SLC5A2 and hydrops fetalis: EGCG’s metabolic and anti-fibrotic effects are highly complementary to the recent mechanistic discoveries of sodium-glucose co-transporter 2 (SGLT2) inhibitors, which have revolutionized HF treatment.